ARS Pharmaceuticals (SPRY) EPS (Basic) (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported EPS (Basic) of -$0.97 for Q1 2026, down 153.74% on a YoY basis from $1.8 in Q1 2025, and down 118.08% sequentially from -$0.44 in Q4 2025.
ARS Pharmaceuticals (SPRY) EPS (Basic) (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of EPS (Basic) data on file, last reported at -$0.97 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) fell 153.74% year-over-year to -$0.97; the trailing twelve-month figure through Mar 2026 stood at -$4.78 (down 120.27% YoY), and the FY2025 full-year result was -$1.74, down 2206.35% from the prior year.
- EPS (Basic) slipped to -$0.97 in Q1 2026, from -$0.44 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $0.49 in Q4 2024 to a low of -$418.21 in Q1 2023.
- A 5-year average of -$58.36 and a median of -$0.7 in 2024 frame the typical range for EPS (Basic).
- Across the five-year window, EPS (Basic) sank 126507.86% in 2023 and jumped 563.49% in 2024, its largest moves.
- Tracing SPRY's EPS (Basic) over 5 years: stood at -$0.38 in 2022, then surged by 72.23% to -$0.11 in 2023, then jumped by 563.49% to $0.49 in 2024, then tumbled by 190.86% to -$0.44 in 2025, then sank by 118.08% to -$0.97 in 2026.
- Business Quant data shows SPRY's EPS (Basic) at -$0.97 in Q1 2026, -$0.44 in Q4 2025, and -$1.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -0.97 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.97 |
| Dec 31, 2025 | -0.44 |
| Sep 30, 2025 | -1.14 |
| Jun 30, 2025 | -2.26 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | 0.49 |
| Sep 30, 2024 | -1.60 |
| Jun 30, 2024 | -0.70 |
| Mar 31, 2024 | -0.94 |
| Dec 31, 2023 | -0.11 |
| Sep 30, 2023 | -161.76 |
| Jun 30, 2023 | -402.49 |
| Mar 31, 2023 | -418.21 |
| Dec 31, 2022 | -0.38 |
| Sep 30, 2022 | -0.43 |
| Jun 30, 2022 | -0.39 |
| Mar 31, 2022 | -0.33 |
| Dec 31, 2021 | 1.35 |
| Sep 30, 2021 | -1.27 |
| Jun 30, 2021 | -4.18 |